Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.

MLA

Björnebo, Lars, et al. “Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.” JAMA Network Open, vol. 7, no. 4, Apr. 2024, p. e247131. EBSCOhost, https://doi.org/10.1001/jamanetworkopen.2024.7131.

APA

Björnebo, L., Discacciati, A., Falagario, U., Vigneswaran, H. T., Jäderling, F., Grönberg, H., Eklund, M., Nordström, T., & Lantz, A. (2024). Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial. JAMA Network Open, 7(4), e247131. https://doi.org/10.1001/jamanetworkopen.2024.7131

Chicago

Björnebo, Lars, Andrea Discacciati, Ugo Falagario, Hari T Vigneswaran, Fredrik Jäderling, Henrik Grönberg, Martin Eklund, Tobias Nordström, and Anna Lantz. 2024. “Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.” JAMA Network Open 7 (4): e247131. doi:10.1001/jamanetworkopen.2024.7131.